글로벌 결절성 경화증 약물 시장 – 2031년까지의 산업 동향 및 예측

결절성 경화증 약물 시장 분석 및 규모

결절성 경화증 약물 시장은 기술과 치료 방법의 발전으로 인해 상당한 성장을 경험하고 있습니다. 최신 치료법은 환자의 결과와 삶의 질을 향상시키고 있으며, 이 복잡한 상태를 관리하는 데 있어 변혁의 시기를 보여줍니다. 연구 및 개발 노력이 증가함에 따라 시장은 더욱 확장될 준비가 되어 있으며, 미래에 개선된 관리와 잠재적으로 치유적인 치료법에 대한 희망을 제공합니다.                                

글로벌 결절성 경화증 약물 시장 규모는 2023년에 8억 3,120만 달러로 평가되었으며, 2031년까지 1,45290만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 7.23%입니다. 이는 시장 가치를 나타냅니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

Market Definition

Tuberous sclerosis complex (TSC) is managed with several medications, primarily targeting symptoms such as seizures, tumors, and skin manifestations. Anti-seizure drugs such as vigabatrin and mTOR inhibitors such as everolimus are commonly prescribed. These medications help control epilepsy and reduce tumor growth associated with TSC. Treatment plans are tailored to individual symptoms and severity to improve quality of life for affected individuals.           

Tuberous Sclerosis Drug Market Dynamics

Drivers

• Increasing Awareness and Diagnosis

The growing awareness of tuberous sclerosis complex (TSC) among healthcare providers and patients is significantly increasing tuberous sclerosis diagnosis rates worldwide. As more cases are identified, the patient pool requiring treatment expands, driving demand for effective therapies. For instance, awareness campaigns by organizations such as the Tuberous Sclerosis Alliance have led to earlier detection and intervention, highlighting the urgent need for innovative drugs to meet the rising medical needs of diagnosed individuals.

• Advancements in Research and Development

Advancements in research and development for tuberous sclerosis complex (TSC) are pivotal in driving the market forward. By deepening our understanding of TSC's molecular pathways, researchers aim to develop highly targeted therapies that can effectively treat the disease's root causes. For instance, ongoing studies into mTOR inhibitors, such as everolimus, have shown promise in managing TSC-related manifestations, spurring further investment and innovation in drug development to meet the growing demand for more effective tuberous sclerosis treatment.

Opportunities

• Lifestyle and Healthcare Expenditure

Rising global healthcare expenditures and a growing willingness to invest in orphan drugs are pivotal drivers propelling the tuberous sclerosis drug market. For instance, the increasing adoption of mTOR inhibitors, such as everolimus and sirolimus, which are specifically approved for treating TSC-associated manifestations such as renal angiomyolipomas and subependymal giant cell astrocytomas, underscores the market's responsiveness to innovative therapies. This trend reflects heightened efforts to enhance patient outcomes and expand treatment options in the rare disease sector.

• Rising Patient Advocacy and Support

Patient advocacy groups for tuberous sclerosis complex (TSC) play a pivotal role in expanding the drug market by advocating for better access to treatments and favorable reimbursement policies. Their efforts ensure that innovative therapies, such as mTOR inhibitors and gene therapies, reach patients worldwide. For instance, the Tuberous Sclerosis Alliance in the United States actively lobbies for increased research funding and policy changes, driving awareness and accelerating market growth for TSC treatments.

Restraints/Challenges

• Rising Complexity of Disease

The complexity of tuberous sclerosis symptoms are different and varying disease severity, poses a significant challenge for drug development. This variability complicates efforts to create effective treatments that comprehensively address the condition's spectrum of manifestations, thereby hindering market prospects. 

• Long-Term Safety and Efficacy Concerns

Long-term safety and efficacy concerns in tuberous sclerosis hinder market acceptance due to the complexity and chronic nature of the disease. Continuous monitoring and reporting of adverse events pose significant challenges, impacting confidence in new treatments and adoption rates among healthcare providers and patients. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Tuberous Sclerosis Drug Market Scope

The market is segmented on the basis of therapy type, route of administration and end- users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy Type

• Laser therapy
• Behavioral Therapy
• Psychiatric Therapy

 Route of Administration

• Oral
• Injectable
• Topical

 End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Tuberous Sclerosis Drug Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, therapy type, route of administration and end- users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the tuberous sclerosis drug market, strengthened by robust health coverage and widespread awareness of the disease and tuberous sclerosis therapy. These factors contribute to a thriving market environment, supporting accessibility and advancements in treatment options for patients.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

의료 인프라 성장 설치 기반 및 신기술 침투

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 결절성 경화증 약물 시장 점유율 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 노바티스 AG(스위스)
• 노벨파마 주식회사(일본)
• 재즈 파마슈티컬스(영국)
• 다케다제약 주식회사(일본)
• Aucta Pharmaceuticals Inc.(영국)
• 석가장 Yiling 제약 유한 회사 (중국)
• H. Lundbeck A/S(덴마크)
• AbbVie Inc.(미국)
•  암젠 주식회사(미국)
• 아스트라제네카(영국)
• Bausch Health Companies Inc. (캐나다)
• F. 호프만-라 로슈 유한회사(스위스)
• 히크마 파마슈티컬스 PLC(요르단)
• 재즈 파마슈티컬스(Jazz Pharmaceuticals, Inc.) (아일랜드)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 파이저 주식회사(미국)

SKU-39843